Top

Published in:

23-11-2023 | Metastasis | Original Paper

Sebaceous carcinoma of the eyelid: demographical analysis and role of surgery in the management

Authors: Abdul Qahar Khan Yasinzai, Mya Goodbee, Jennifer Ahweyevu, Abdul Samad Khan Tareen, Hafeez Ullah, Muhammad Ayub Tareen, Abdul Waheed, Adil Karim, Dauod Arif, Marjan Khan, Luis Brandi, Asad Ullah

Published in: European Journal of Plastic Surgery | Issue 6/2023

Abstract

Background

Eyelid sebaceous carcinoma is an uncommon aggressive cancer its capacity to cause serious harm and death underscores the significance of prompt identification and treatment. This study aims to evaluate the demographic, clinical, and pathological factors that impact the prognosis and survival of individuals with eyelid sebaceous carcinoma.

Methods

The data for this study was abstracted from the Surveillance, Epidemiology, and End Results (SEER) database from 2000–2018. The demographic and clinical data included several parameters, such as age, race, tumor grade, tumor size, surgical treatment, radiotherapy, chemotherapy, overall survival, and survival with specific treatments. The proportional hazard regression model was employed in this study to calculate hazard ratios and ascertain independent factors affecting survival outcomes. Data points with unidentified or missing values were excluded from the multivariate analysis to ensure robustness.

Results

A total 0f 903 of sebaceous carcinomas were extracted from the database. The mean age was 71.7 years and the majority (83.2%) were over 60 years old with a slight predominance of women (56.7%). Race was known for (96.6%) of cases, with White being the most dominant (86.6%) followed by Asian or Pacific Islander (10.2%). When tumor grade was known, poorly differentiated accounted for the majority (53.1%). Most cases with known tumor size were > 10 mm (44.9%). Where metastasis status was known, no metastasis was found in (99.2%). Most patients (80.2%) were treated with surgery alone. Being White and male had a better 5-year survival of 93.9% with a 95% confidence interval (C.I 95%) (C.I 95%, 61.3–99.0) and 95.3% (C.I 95%, 91.3–97.4) respectively. Multivariable analysis identified tumor size > 10 mm and age > 60 as independent risk factors for mortality (p < 0.010).

Conclusions

Our study found that old age and large tumor size are negative prognostic factors. Future research should target novel molecular targets and effective combination therapies to improve patient outcomes.

Level of evidence: Level III, Therapeutic; Diagnostic; Risk/Prognostic

Available only for authorised users

Tripathi R, Chen Z, Li L, Bordeaux JS (2016) Incidence and survival of sebaceous carcinoma in the United States. J Am Acad Dermatol 75(6):1210–1215. https://doi.org/10.1016/j.jaad.2016.07.0462CrossRefPubMed

Shields JA, Saktanasate J, Lally SE, Carrasco JR, Shields CL (2015) Sebaceous carcinoma of the ocular region: the 2014 professor winifred mao lecture. Asia Pac J Ophthalmol (Phila) 4(4):221–227. https://doi.org/10.1097/APO.00000000000001053CrossRefPubMed

Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL (2005) Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol 50(2):103–122CrossRefPubMed

Muqit MM, Foot B, Walters SJ, Mudhar HS, Roberts F, Rennie IG (2013) Observational prospective cohort study of patients with newly-diagnosed ocular sebaceous carcinoma. Br J Ophthalmol 97(1):47–51. https://doi.org/10.1136/bjophthalmol-2012-302443CrossRefPubMed

Sargen MR, Mai ZM, Engels EA, Goldstein AM, Tucker MA, Pfeiffer RM et al (2020) Ambient ultraviolet radiation and sebaceous carcinoma incidence in the United States, 2000–2016. JNCI Cancer Spectr 4(2):pkaa020. https://doi.org/10.1093/jncics/pkaa020CrossRefPubMedPubMedCentral

Hussain RM, Matthews JL, Dubovy SR, Thompson JM, Wang G (2014) UV-independent p53 mutations in sebaceous carcinoma of the eyelid. Ophthalmic Plast Reconstr Surg 30(5):392–395. https://doi.org/10.1097/IOP.0000000000000121CrossRefPubMed

Rajan KdA, Burris C, Iliff N, Grant M, Eshleman JR, Eberhart CG (2014) DNA mismatch repair defects and microsatellite instability status in periocular sebaceous carcinoma. Am J Ophthalmol 157(3):640–7.e72. https://doi.org/10.1016/j.ajo.2013.12.002CrossRef

North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W et al (2018) Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun 9(1):1894. https://doi.org/10.1038/s41467-018-04008-y.PMID:29760388;PMCID:PMC5951856CrossRefPubMedPubMedCentral

Dores GM, Curtis RE, Toro JR, Devesa SS, Fraumeni JF Jr (2008) Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: insight into Muir-Torre syndrome. Cancer 113(12):3372–3381. https://doi.org/10.1002/cncr.23963CrossRefPubMed

10.

Owen JL, Kibbi N, Worley B, Kelm RC, Wang JV, Barker CA et al (2019) Sebaceous carcinoma: evidence-based clinical practice guidelines. Lancet Oncol 20(12):e699–e714. https://doi.org/10.1016/S1470-2045(19)30673-4CrossRefPubMed

11.

Flux K (2017) Sebaceous neoplasms. Surg Pathol Clin 10(2):367–382. https://doi.org/10.1016/j.path.2017.01.009CrossRefPubMed

12.

Grossniklaus HE, Eberhart CG, Kivela TT (2018) WHO classification of tumours of the eye, 4th edn. World Health Organization Classification of Tumours. International Agency for Research on Cancer, Lyon

13.

Knackstedt T, Samie FH (2017) Sebaceous carcinoma: a review of the scientific literature. Curr Treat Options Oncol 18(8):47. https://doi.org/10.1007/s11864-017-0490-0CrossRefPubMed

14.

Cicinelli MV, Kaliki S (2019) Ocular sebaceous gland carcinoma: an update of the literature. Int Ophthalmol 39(5):1187–1197. https://doi.org/10.1007/s10792-018-0925-zCrossRefPubMed

15.

Phan K, Loya A (2019) Mohs micrographic surgery versus wide local excision for sebaceous adenocarcinoma of the eyelid : Analysis of a national database. J Plast Reconstr Aesthet Surg 72(6):1007–1011CrossRefPubMed

16.

Husain A, Blumenschein G, Esmaeli B (2008) Treatment and outcomes for metastatic sebaceous cell carcinoma of the eyelid. Int J Dermatol 47(3):276–279CrossRefPubMed

17.

Goto H, Tsubota K, Nemoto R, Ueda S, Umazume K, Usui Y et al (2020) Clinical features and prognosis of sebaceous carcinoma arising in the eyelid or conjunctiva. Jpn J Ophthalmol 64(5):549–554. https://doi.org/10.1007/s10384-020-00756-xCrossRefPubMed

18.

Zürcher M, Hintschich CR, Garner A, Bunce C, Collin JR (1998) Sebaceous carcinoma of the eyelid: a clinicopathological study. Br J Ophthalmol 82(9):1049–1055. https://doi.org/10.1136/bjo.82.9.1049CrossRefPubMedPubMedCentral

19.

Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL (2004) Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology 111(12):2151–2157. https://doi.org/10.1016/j.ophtha.2004.07.031CrossRefPubMed

20.

Callahan EF, Appert DL, Roenigk RK, Bartley GB (2004) Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg 30(8):1164–1168. https://doi.org/10.1111/j.1524-4725.2004.30348.xCrossRefPubMed

21.

Hou JL, Killian JM, Baum CL, Otley CC, Roenigk RK, Arpey CJ et al (2014) Characteristics of sebaceous carcinoma and early outcomes of treatment using Mohs micrographic surgery versus wide local excision: an update of the Mayo Clinic experience over the past 2 decades. Dermatol Surg 40(3):241–246. https://doi.org/10.1111/dsu.12433CrossRefPubMed

22.

Spencer JM, Nossa R, Tse DT, Sequeira M (2001) Sebaceous carcinoma of the eyelid treated with Mohs micrographic surgery. J Am Acad Dermatol 44(6):1004–1009. https://doi.org/10.1067/mjd.2001.113692CrossRefPubMed

23.

Takagawa Y, Tamaki W, Suzuki S, Inaba K, Murakami N, Takahashi K et al (2019) Radiotherapy for localized sebaceous carcinoma of the eyelid: a retrospective analysis of 83 patients. J Radiat Res 60(5):622–629. https://doi.org/10.1093/jrr/rrz046CrossRefPubMedPubMedCentral

24.

Hata M, Koike I, Omura M, Maegawa J, Ogino I, Inoue T (2012) Noninvasive and curative radiation therapy for sebaceous carcinoma of the eyelid. Int J Radiat Oncol Biol Phys 82(2):605–611. https://doi.org/10.1016/j.ijrobp.2010.12.006CrossRefPubMed

25.

Yin VT, Merritt HA, Sniegowski M, Esmaeli B (2015) Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol 33(2):159–69. https://doi.org/10.1016/j.clindermatol.2014.10.008CrossRefPubMed

26.

Sa HS, Rubin ML, Xu S, Ning J, Tetzlaff M, Sagiv O et al (2019) Prognostic factors for local recurrence, metastasis and survival for sebaceous carcinoma of the eyelid: observations in 100 patients. Br J Ophthalmol 103(7):980–984. https://doi.org/10.1136/bjophthalmol-2018-312635CrossRefPubMed

27.

Ponti G, de Leon MP (2005) Muir-Torre syndrome. Lancet Oncol 6(12):980–987CrossRefPubMed

28.

Cohen PR, Kohn R, Kurzrock R (1991) Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med 90(5):606–613CrossRefPubMed

29.

Gaskin BJ, Fernando BS, Sullivan CA, Whitehead K, Sullivan TJ (2011) The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome. Br J Ophthalmol 95(12):1686–1690. https://doi.org/10.1136/bjophthalmol-2011-300612CrossRefPubMed

30.

Kwon MJ, Nam ES, Cho SJ, Park HR, Min SK, Seo J et al (2017) Mutation analysis of CTNNB1 gene and the ras pathway genes KRAS, NRAS, BRAF, and PIK3CA in eyelid sebaceous carcinomas. Pathol Res Pract 213(6):654–658. https://doi.org/10.1016/j.prp.2017.02.015CrossRefPubMed

31.

Kodama T, Hayasaka S, Setogawa T (1995) Immunohistochemical localization of epidermal growth factor receptor and epithelial antigen in tumors of the human conjunctiva, eyelid, lacrimal gland, and orbit. Graefes Arch Clin Exp Ophthalmol 233:672–676CrossRefPubMed

32.

Yin VT, Merritt H, Esmaeli B (2014) Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomas. World J Clin Cases 2(9):432–438CrossRefPubMedPubMedCentral

33.

Domingo-Musibay E, Murugan P, Giubellino A, Sharma S, Steinberger D, Yuan J, Hunt MA, Lou E, Miller JS (2018) Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma. J Immunother Cancer 6(1):58. https://doi.org/10.1186/s40425-018-0357-3CrossRefPubMedPubMedCentral

34.

Jayaraj P, Sen S (2019) Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance. Indian J Ophthalmol 67(12):1983–1987CrossRefPubMedPubMedCentral

Title: Sebaceous carcinoma of the eyelid: demographical analysis and role of surgery in the management
Authors: Abdul Qahar Khan Yasinzai
Mya Goodbee
Jennifer Ahweyevu
Abdul Samad Khan Tareen
Hafeez Ullah
Muhammad Ayub Tareen
Abdul Waheed
Adil Karim
Dauod Arif
Marjan Khan
Luis Brandi
Asad Ullah
Publication date: 23-11-2023
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Muir-Torre Syndrome
Published in: European Journal of Plastic Surgery / Issue 6/2023
Print ISSN: 0930-343X
Electronic ISSN: 1435-0130
DOI: https://doi.org/10.1007/s00238-023-02137-2

2024 ASCO Annual Meeting

Springer Medicine

Sebaceous carcinoma of the eyelid: demographical analysis and role of surgery in the management

Abstract

Background

Methods

Results

Conclusions

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2023

An update and overview of the literature on late inflammatory reactions (LIRs) in soft tissue fillers after SARS-CoV-2 infection and vaccination

The spiral flap for breast auto-augmentation revisited

Microvascular surgery training in a low volume setting: a single healthcare center experience

How can we inspire junior trainees to consider a career in plastic surgery as a basis to pursue humanitarian work?

Analysis of complications following implant-based breast reconstruction in breast cancer patients

A retrospective cohort study comparing donor site morbidity between the L-shaped upper gracilis and transverse upper gracilis flap in breast reconstruction